Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate and compare the safety and efficacy of an oral dual
tyrosine kinase inhibitor, lapatinib, versus placebo in women with early-stage
ErbB2-overexpressing breast cancer who have completed their primary neoadjuvant or adjuvant
chemotherapy and have no clinical or radiographic evidence of disease.